Novartis and Gilead’s CAR-T therapies have been approved in Europe – and the UK’s NICE immediately slapped down the latter, saying it is too expensive for regular NHS use in England and Wal
Gilead may be looking for a deal-broker who can kick-start the company’s growth after the lacklustre launch of its CAR-T therapy, after CEO John Milligan announced he is to step down at the
